Update of the STIKO recommendation on vaccination against pneumococcal disease for children and adolescents with risk factors aged ≥ 2 to 17 years

In addition to young children and older adults, people with risk factors or underlying medical conditions also have an increased risk of developing severe pneumococcal disease. Indication based vaccinations are recommended for this group. Due to the availability of a 20-valent pneumococcal conjugate vaccine (PCV20), the STIKO is updating its recommendation on vaccination for children and adolescents aged ≥ 2 to 17 years with risk factors for severe pneumococcal disease, taking into account the available evidence on the safety and efficacy of PCV20.